Reducing the dose and duration of the tamoxifen-induction regimen in the K5:BRAFV600E and K14:BRAFV600E models delayed tumour onset, but tumours still grew rapidly (Supplementary Fig. 2c). This evidence concerns the gene KRT14 and neoplasm.